

OXFORD CARDIOLOGY LIBRARY



Management of Atrial Fibrillation

A Practical Approach

Edited by

MOHAMMAD SHENASA

A. JOHN CAMM

Management of Atrial Fibrillation

A Practical Approach

Edited by

Mohammad Shenasa MD

Attending Physician
Department of Cardiovascular Services
O'Connor Hospital;
Heart & Rhythm Medical Group
San Jose, CA, USA

A. John Camm MD

Professor of Clinical Cardiology
Department of Clinical Sciences
St George's and University of London
London, UK

OXFORD

UNIVERSITY PRESS

Great Clarendon Street, Oxford, OX2 6DP,
United Kingdom

Oxford University Press is a department of the University of Oxford.
It furthers the University's objective of excellence in research, scholarship,
and education by publishing worldwide. Oxford is a registered trade mark of
Oxford University Press in the UK and in certain other countries

© Oxford University Press 2015

The moral rights of the authors have been asserted

Impression: 1

All rights reserved. No part of this publication may be reproduced, stored in
a retrieval system, or transmitted, in any form or by any means, without the
prior permission in writing of Oxford University Press, or as expressly permitted
by law, by licence or under terms agreed with the appropriate reprographics
rights organization. Enquiries concerning reproduction outside the scope of the
above should be sent to the Rights Department, Oxford University Press, at the
address above

You must not circulate this work in any other form
and you must impose this same condition on any acquirer

Published in the United States of America by Oxford University Press 198
Madison Avenue, New York, NY 10016, United States of America

British Library Cataloguing in Publication Data
Data available

Library of Congress Control Number: 2014947265

ISBN 978-0-19-968631-5

Printed in Great Britain by
Ashford Colour Press Ltd, Gosport, Hampshire

Oxford University Press makes no representation, express or implied, that the
drug dosages in this book are correct. Readers must therefore always check
the product information and clinical procedures with the most up-to-date
published product information and data sheets provided by the manufacturers
and the most recent codes of conduct and safety regulations. The authors and
the publishers do not accept responsibility or legal liability for any errors in the
text or for the misuse or misapplication of material in this work. Except where
otherwise stated, drug dosages and recommendations are for the non-pregnant
adult who is not breastfeeding.

4.6 Atrial fibrillation and coronary artery disease including acute myocardial infarction

CAD is another major risk factor for AF and increases the risk of AF by four- to fivefold. AF in the setting of chronic CAD and previous myocardial infarction (presence of scar tissue)

Material protected by copyright

is a dangerous combination that promotes malignant ventricular arrhythmias and increases the risk of SCD.

AF is a common complication of acute myocardial infarctions (occurring in 6–13% of patients presenting with acute myocardial infarction) and poses an increased risk of morbidity, mortality, prolongs the hospital stay, and may facilitate spontaneous initiation of ventricular tachyarrhythmias. Pedersen et al. (2006) reported that AF and atrial flutter following acute myocardial infarction increase the risk of both sudden and non-sudden cardiovascular death. The combination of CAD and AF also complicates the antithrombotic management strategy for both conditions. AF management with antiarrhythmic therapy in this setting increases the risk of proarrhythmias and SCD. This relationship is further complicated in the setting of acute myocardial infarction. Berton et al. (2009) recently reported on a 7-year follow-up of the adverse effect of AF during acute myocardial infarction. The study comprised 505 patients who were admitted to intensive care units with definite acute myocardial infarction. After adjusting for other co-risk factors, incident AF or atrial flutter was associated with poor prognosis in long-term follow-up, specifically an increased risk of SCD. Management strategies should focus on prevention of AF and atrial flutter in this setting including antiarrhythmic therapy, antithrombotic therapy, and ICD therapy for patients at high risk of SCD. (See Chapter 5.)

- Amat-Santos IJ, Rodes-Cabau J, Urena M, DeLarochelliere R, Doyle D, et al. (2012). Incidence, predictive factors and prognostic value of new-onset atrial fibrillation following transcatheter aortic valve implantation. *J Am Coll Cardiol* 59: 178–88.
- Anter E, Jessup M, Callans DJ (2009). Atrial fibrillation and heart failure: treatment considerations for a dual epidemic. *Circulation* 119: 2516–25.
- Baber U, Howard VJ, Halperin JL, Soliman E, Zhang X, McClellan W, et al. (2011). Association of chronic kidney disease with atrial fibrillation among adults in the United States: REasons for Geographic and Racial Differences in Stroke (REGARDS) Study. *Circ Arrhythm Electrophysiol* 4: 26–32.
- Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GYH, et al. (2012). Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. *Eur J Heart Fail* 14: 295–301.
- Bansal N, Fan D, Hsu C, Ordonez JD, Marcus GM, Go AS (2013). Incident atrial fibrillation and risk of end-stage renal disease in adults with chronic kidney disease. *Circulation* 127: 569–74.
- Barrett TW, Abraham RL, Jenkins CA, Russ S, Storrow AB, Darbar D (2012). Risk factors for bradycardia requiring pacemaker implantation in patients with atrial fibrillation. *Am J Cardiol* 110: 1315–21.
- Belhassen B (2013). Continuous positive airway pressure after circumferential pulmonary vein isolation. *J Am Coll Cardiol* 62(4): 306–7.
- Benjamin EJ, Chen PS, Bild DE, Mascette AM, Albert CM, Alonso A, et al. (2009). Prevention of atrial fibrillation: report from a national heart, lung and blood institute workshop. *Circulation* 119: 606–18.
- Benjamin EJ, Levy D, Vazisiri SM, D'Agostino RB, Belanger AJ, Wolf PA (1994). Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. *JAMA* 271: 840–4.
- Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D (1998). Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. *Circulation* 98: 946–52.
- Berti D, Hindriks JML, Brandes A, Deaton C, Crijns HJGM, Camm AJ, et al. (2013). A proposal for interdisciplinary nurse-coordinated atrial fibrillation expert programmes as a way to structure daily practice. *Eur Heart J* 34: 2725–30.
- Berton G, Cordiano R, Cucchini F, Cavuto F, Pellegrinet M, Palatini P (2009). Atrial fibrillation during acute myocardial infarction: association with all-cause mortality and sudden death after 7-year follow up. *Int J Clin Pract* 63: 712–21.
- Bigi MA, Aslani A, Shahrzad S (2007). Clinical predictors of atrial fibrillation in Brugada syndrome. *Europace* 9: 947–50.